Sanara Medtech Inc. · NASDAQ:SMTI
Sanara Medtech — Q2 2021 Earnings Presentation
8 slides from Sanara Medtech's earnings presentation, Aug 16, 2021
Slide 1: Q2 2021 Earnings and Business Update Call
Q2 2021 Earnings and Business Update Call
Slide 2: Disclaimers
Disclaimers This presentation contains forward-looking statements that discuss expectations as to future trends, plans, events, results of operations or financial condition, or state other information relating to Sanara MedTech Inc. (the “Company,” “Sanara,” “we,” “our” or “us”). All statements othe
Slide 3: Overview
Overview Commentary on Q2 2021 • Financial Update • Record revenue quarter with sales of $6.3 million and a net loss of $1.2 million driven by continued growth in surgical product sales • Cash on hand: $24.4 million at the end of the quarter • Surgical Products Sales • Continuing focus on increasing
Slide 4: Surgical Products
Surgical Products Surgical Overview • 26 Regional Sales Managers (“RSMs”) and Territory Sales Managers (“TSMs”) • CellerateRX Surgical sold in over 300 hospitals/ASCs as of June 30, 2021 • CellerateRX Surgical sold in hospitals/ASCs across 21 states(1) as of June 30, 2021 • CellerateRX Surgical appr
Slide 5: Cook - Sanara Partnership Products
Cook - Sanara Partnership Products • Executed in December 2020 • Exclusive marketing agreement for Sanara to purchase, market, and distribute three advanced biologics products: ― FORTIFY TRGTM Tissue Repair Graft ― FORTIFY FLOWABLETM Extracellular Matrix ― VIMTM Amnion Matrix FORTIFY TRGTM Tissue Re
Slide 6: Product Pipeline
Product Pipeline CuraShield Anti-Microbial Debridement Technology Next Generation CellerateRX Next Generation HYCOL BIASURGE Barrier Film • Intended for application • Leverages the body’s own • Second generation • Second generation • Sterile BIAKŌS product on minor wounds and enzymes and moisture t
Slide 7: Q2 2021 Financial Highlights
Q2 2021Financial Highlights Overview • Revenue • Generated $6.3 million in revenue for the three months ended June 30, 2021 versus $3 million for the three months ended June 30, 2020 (112% increase) • Generated $11.3 million in revenue for the six months ended June 30, 2021 versus to $6.5 million fo
Slide 8: Rochal Asset Acquisition
Rochal Asset Acquisition Purchase Price • Approximately $1.0 million, consisting of $0.5 million in Sanara common stock and approximately $0.5 million in cash Continued Partnership and Parallel Interests • Sanara has right of first refusal for excluded products currently under development. • If Sana